The Stryker Regenkit PRP Kit Does Not Concentrate Canine Platelets

Area of Science:

• Veterinary Medicine
• Regenerative Medicine
• Biotechnology

Background:

• Platelet-Rich Plasma (PRP) therapy utilizes growth factors and anti-inflammatory mediators to enhance healing in compromised tissues like joints, tendons, and ligaments.
• Existing research indicates significant variability in the cellular composition of PRP products generated by different systems.
• Understanding the specific cellular output of various PRP systems is crucial for effective clinical application in veterinary medicine.

Purpose of the Study:

• To evaluate the cellular composition of Platelet-Rich Plasma (PRP) produced by the Stryker RegenKit system in a canine model.
• To compare the final PRP product's platelet, erythrocyte, and leukocyte counts against the initial peripheral blood counts in dogs.

Main Methods:

• Peripheral blood samples were collected from ten healthy adult dogs.
• A subset of blood was processed using the Stryker RegenKit according to manufacturer guidelines to obtain PRP.
• Complete Blood Counts (CBC) were performed on both peripheral blood and the final PRP product for comparative analysis.

Main Results:

• No statistically significant difference was observed in mean platelet counts between peripheral blood and the final PRP product (p = 0.349).
• Significantly lower concentrations of erythrocytes were found in the final PRP product compared to peripheral blood (p < 0.0001).
• Leukocyte concentrations were also significantly reduced in the final PRP product relative to peripheral blood (p = 0.0318).

Conclusions:

• The Stryker RegenKit system effectively reduces erythrocyte and leukocyte concentrations in its final PRP product for canine use.
• The system does not consistently alter platelet concentrations, a key component for therapeutic efficacy.
• These findings, alongside other PRP system evaluations, can guide veterinarians in selecting optimal PRP devices for treating canine musculoskeletal conditions.